These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22280363)
41. Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A. Zhang B; Shan G; Zheng Y; Yu X; Ruan ZW; Li Y; Lei X Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31163697 [TBL] [Abstract][Full Text] [Related]
42. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation. Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364 [TBL] [Abstract][Full Text] [Related]
44. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects. Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472 [TBL] [Abstract][Full Text] [Related]
45. Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification. Jing Q; Hu X; Ma Y; Mu J; Liu W; Xu F; Li Z; Bai J; Hua H; Li D Mar Drugs; 2019 Jun; 17(7):. PubMed ID: 31252563 [TBL] [Abstract][Full Text] [Related]
46. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Cheng J; Qin J; Guo S; Qiu H; Zhong Y Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565 [TBL] [Abstract][Full Text] [Related]
47. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Kim HJ; Kim JH; Chie EK; Young PD; Kim IA; Kim IH Radiat Oncol; 2012 Mar; 7():39. PubMed ID: 22429326 [TBL] [Abstract][Full Text] [Related]
48. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors. Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751 [TBL] [Abstract][Full Text] [Related]
49. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis. Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520 [TBL] [Abstract][Full Text] [Related]
50. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. Suzuki T; Kouketsu A; Itoh Y; Hisakawa S; Maeda S; Yoshida M; Nakagawa H; Miyata N J Med Chem; 2006 Aug; 49(16):4809-12. PubMed ID: 16884291 [TBL] [Abstract][Full Text] [Related]
52. Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. McCulloch MW; Coombs GS; Banerjee N; Bugni TS; Cannon KM; Harper MK; Veltri CA; Virshup DM; Ireland CM Bioorg Med Chem; 2009 Mar; 17(6):2189-98. PubMed ID: 19022675 [TBL] [Abstract][Full Text] [Related]
53. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Kong Y; Jung M; Wang K; Grindrod S; Velena A; Lee SA; Dakshanamurthy S; Yang Y; Miessau M; Zheng C; Dritschilo A; Brown ML Mol Cancer Ther; 2011 Sep; 10(9):1591-9. PubMed ID: 21697394 [TBL] [Abstract][Full Text] [Related]
54. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity. Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013 [TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents. Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298 [TBL] [Abstract][Full Text] [Related]
57. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Ahn MY; Jung JH; Na YJ; Kim HS Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664 [TBL] [Abstract][Full Text] [Related]
58. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078 [TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178 [TBL] [Abstract][Full Text] [Related]
60. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. Xie R; Li Y; Tang P; Yuan Q Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]